Insight, China's Pharmaceutical Industry

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) announced that China’s National Medical Products Administration (NMPA) has granted...

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026

Gan & Lee Pharmaceuticals (SHA: 603087) announced a licensing agreement with JW Pharmaceutical, granting the South...

Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced a strategic partnership with The University of Hong...

Company Drug

Sino Biopharm’s Chia Tai Tianqing Secures GDMPA Approval for Naldemedine in Greater Bay Area – World’s First Oral OIC Therapy Enters China

Fineline Cube Apr 9, 2026

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a wholly‑owned subsidiary of Sino Biopharmaceutical Limited...

Company Drug

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Fineline Cube Apr 9, 2026

UniXell Biotechnology, a clinical-stage cell therapy innovator, announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Fineline Cube Apr 9, 2026

Shionogi Co., Ltd. (TYO: 4507) announced that its U.S. subsidiary, Shionogi Inc., has been awarded...

Others

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Fineline Cube Apr 8, 2026

Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30...

Others

Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions

Fineline Cube Apr 8, 2026

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, announced...

Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026

Wuhan Ammunition Life-tech Co., Ltd. has filed its prospectus for an initial public offering (IPO)...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Fineline Cube Apr 8, 2026

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) announced that China’s National Medical Products Administration...

Company Drug

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Fineline Cube Apr 8, 2026

Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Others

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Fineline Cube Apr 8, 2026

Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of...

Company Drug

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Fineline Cube Apr 8, 2026

Sanofi (NASDAQ: SNY) announced positive top-line results from two Phase II clinical studies of lunsekimig,...

Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026

Gilead Sciences Inc. (NASDAQ: GILD) announced a definitive agreement to acquire Tubulis GmbH, a German...

Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026

Biogen Inc. (NASDAQ: BIIB) announced a strategic licensing agreement with Alloy Therapeutics Inc., securing access...

Company Drug

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

Fineline Cube Apr 8, 2026

Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast...

Company Deals

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Fineline Cube Apr 8, 2026

Everest Medicines (HKG: 1952) announced a definitive agreement to acquire 100% of the equity interests...

Company Deals

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

Fineline Cube Apr 8, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502, NYSE: TAK) announced the termination of its neuroscience collaboration...

Company Drug

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Fineline Cube Apr 8, 2026

GlaxoSmithKline plc (GSK, NYSE: GSK) announced that China’s National Medical Products Administration (NMPA) has granted...

Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026

The Beijing Municipal Medical Insurance Bureau, in coordination with nine other government bureaus, has released...

Insight, China's Pharmaceutical Industry

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Sino Biopharm’s Chia Tai Tianqing Secures GDMPA Approval for Naldemedine in Greater Bay Area – World’s First Oral OIC Therapy Enters China

UniXell Biotechnology Secures NMPA IND Approval for UX-GIP001, World’s First iPSC-Derived Cell Therapy for Drug-Resistant Epilepsy

Shionogi Secures $119M BARDA Contract for Fetroja Antibiotic as Biothreat Countermeasure

Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission

Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Joincare Pharmaceutical Receives NMPA Approval to Initiate JKN2401 Clinical Study in CRSwNP, Expanding TSLP-Targeting Biologic Development Across Respiratory Indications

Haisco Pharmaceutical Secures NMPA Breakthrough Therapy Designation for HSK39004 Inhalation Powder in COPD, Following Successful Phase II Lung Function Data

Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders

Sanofi’s Bispecific Nanobody Lunsekimig Achieves Primary Endpoints in Asthma and CRSwNP Phase II Studies, Shows Mixed Results in Atopic Dermatitis

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Simcere’s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure

Everest Medicines to Acquire EverSea Medicines Singapore for $250M, Expanding Asia-Pacific Chronic Disease Portfolio

Takeda Terminates Neuroscience Partnership with Denali, Returns Frontotemporal Dementia Candidate DNL593 for Strategic Realignment

GSK’s Exdensur Secures Second NMPA Approval in China for Chronic Rhinosinusitis with Nasal Polyps, Expanding Type 2 Inflammation Portfolio

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

You Missed

AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data

RemeGen’s Disitamab Vedotin Wins World’s First HER2-ADC Approval for First-Line Advanced Urothelial Carcinoma

Henlius Biotech Doses First Patient in Phase I Trial for HLX319, a Biosimilar to Roche’s Phesgo

AbbVie Secures NMPA Label Expansion for Rinvoq in China, Clarifying Use in UC and Crohn’s Disease